The DOI matches its Crossref record, with a small difference in title or year; 80 of the 80 references it cites were found in a registry or an index.
Diabetic Kidney Disease: Challenges, Progress, and Possibilities
Open accessAbstract
Diabetic kidney disease develops in approximately 40% of patients who are diabetic and is the leading cause of CKD worldwide. Although ESRD may be the most recognizable consequence of diabetic kidney disease, the majority of patients actually die from cardiovascular diseases and infections before needing kidney replacement therapy. The natural history of diabetic kidney disease includes glomerular hyperfiltration, progressive albuminuria, declining GFR, and ultimately, ESRD. Metabolic changes associated with diabetes lead to glomerular hypertrophy, glomerulosclerosis, and tubulointerstitial inflammation and fibrosis. Despite current therapies, there is large residual risk of diabetic kidney disease onset and progression. Therefore, widespread innovation is urgently needed to improve health outcomes for patients with diabetic kidney disease. Achieving this goal will require characterization of new biomarkers, designing clinical trials that evaluate clinically pertinent end points, and development of therapeutic agents targeting kidney-specific disease mechanisms ( e.g. , glomerular hyperfiltration, inflammation, and fibrosis). Additionally, greater attention to dissemination and implementation of best practices is needed in both clinical and community settings.Introduction
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The pathogenesis of DKD involves a complex interplay of hyperglycaemia-induced metabolic alterations, haemodynamic changes and various types of intracellular stress.”
From Autophagy in kidney homeostasis and disease (2020) · cites this paper as [126]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Diabetic kidney disease (DKD) is one of the most common and life-threatening diabetic complications and a leading cause of CKD and kidney failure worldwide126.”
From Autophagy in kidney homeostasis and disease (2020) · cites this paper as [126]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Collectively, these processes induce the production of a range of cytokines, chemokines and growth factors that promote cell injury, inflammation and kidney fibrosis.”
From Autophagy in kidney homeostasis and disease (2020) · cites this paper as [126]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A plausible mechanistic explanation for the renoprotective effect of SGLT2 inhibitors is correction of aberrant glomerular haemodynamics induced by hyperglycaemia, which drive progressive nephron loss.34,35”
From SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis (2019) · cites this paper as [34]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Even with current therapies available [6–10], patients with T2DM and chronic kidney disease (CKD) still experience a significant cardiovascular and renal morbidity and mortality.”
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Research works printed but not linked: 2
- 2016, Standards of medical care in diabetes-2016: Summary of revisions, Diabetes Care, 39, S4
- Bakris, 2015, Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial, JAMA, 314, 884, 10.1001/jama.2015.10081 · DOI · Paper page
Cited by
Kalantar-Zadeh, K., Jafar, T. H., Nitsch, D., Neuen, B. L., & Perkovic, V. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00519-5 · Cited by 1,461
Agarwal, R., Filippatos, G., Pitt, B., Anker, S. D., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Gebel, M., Ruilope, L. M., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab777 · Cited by 1,317
Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment
Samsu, N. (2021) · BioMed Research International · doi:10.1155/2021/1497449 · Cited by 1,001
“Although the true prevalence of nondiabetic kidney disease in diabetic individuals may be <10% [129], this possibility should always be considered and a kidney biopsy must be performed in the presence of certain clinical criteria: (1) short-duration type 1 diabetes, (2) diagnosis of autoimmune disease, (3) mild or abs…”
BackgroundMetabolomics: A New Tool to Reveal the Nature of Diabetic Kidney Disease
Huang, G., Li, M., Li, Y., & Mao, Y. (2022) · Laboratory Medicine · doi:10.1093/labmed/lmac041 · Cited by 922
Neuen, B. L., Young, T., Heerspink, H. J. L., Neal, B., Perkovic, V., Billot, L., Mahaffey, K. W., Charytan, D. M., Wheeler, D. C., Arnott, C., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30256-6 · Cited by 893
Metadata
- Authors
- Alicic, R. Z., Rooney, M. T., & Tuttle, K. R.
- Affiliations
- University of Washington (US)
- Providence Health Care, Spokane, Washington;
- Corresponding author
- Alicic, Radica Z.
- Rooney, Michele T.
- Tuttle, Katherine R.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2017-05-18
- Volume
- 12
- Issue
- 12
- Pages
- 2032-2045
- ISSN
- 1555-9041 (ISSN-L)
- 1555-905X
- PMC
- PMC5718284
- OpenAlex
- W2615714795
- Semantic Scholar
- 5221ad157f1f15727ba86e086ad7b5775982495f
- Cited by
- 2,898
- References
- 80
- Citations by year
- 2026: 430 · 2025: 412 · 2024: 442 · 2023: 458 · 2022: 424 · 2021: 337 · 2020: 246 · 2019: 107 · 2018: 32 · 2017: 8
- FWCI
- 96.16
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Clinical Journal of the American Society of Nephrology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- diabetic nephropathy, chronic kidney disease, end-stage renal disease, glomerular hyperfiltration, albuminuria, glomerulosclerosis, tubulointerstitial fibrosis, cardiovascular mortality, biomarkers, therapeutic target, disease progression, best practice implementation
- MeSH terms
- Diabetic Nephropathies, Glomerular Filtration Rate, Humans, Hyperglycemia, Hypertension, Hypoglycemic Agents, Kidney Failure, Chronic, Risk Factors, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diabetic Kidney Disease: Challenges, Progress, and Possibilities. https://app.cochat.ai/papers/10.2215/cjn.11491116
- The paper
- Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017). Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.11491116
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.